Summit Therapeutics (SMMT) Stock Price

Summit Therapeutics Price

NASDAQ·CLOSED
9.95
​
Market closed

Revenue has compounded at 1.7% per year over the past 17 years to 710,000.00 USD. Summit Therapeutics's net margin stands at -11,095.8%, down from 17.3% several years earlier. Analysts set a median price target of 35.50 USD, implying 256.8% above the current price. Of 24 analysts, 17 rate the stock a buy — an overall Buy consensus.

Summit Therapeutics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Summit Therapeutics business model & stock analysis

Summit Therapeutics Inc. is a global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines for the treatment of life-threatening and rare diseases. The company is headquartered in Massachusetts, USA and also has offices in Oxford, UK.

Frequently asked questions about Summit Therapeutics

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of novel medicines to treat rare and infectious diseases. Their business model revolves around leveraging their expertise in genetic research and drug development to advance innovative therapies. By utilizing their proprietary Discuva Platform, Summit Therapeutics aims to identify potential protein targets for drug discovery and design personalized medicines. With a strong emphasis on precision medicine, their goal is to improve patient outcomes by delivering targeted therapeutics tailored to individual needs. Summit Therapeutics Inc. is dedicated to research and collaboration to address unmet medical needs and enhance global healthcare.

Summit Therapeutics Inc is primarily active in the pharmaceutical industry. With a focus on developing innovative therapies, Summit Therapeutics engages in drug discovery and development for various medical conditions. The company's expertise lies in the research and development of novel antibiotics, specifically targeting the treatment of bacterial infections. Summit Therapeutics works closely with healthcare professionals and regulatory agencies to bring safe and effective therapeutic solutions to patients in need. As a leading player in the pharmaceutical industry, Summit Therapeutics Inc continuously strives to enhance healthcare outcomes and improve the quality of life for individuals worldwide.

The main competitors of Summit Therapeutics Inc in the market include pharmaceutical companies such as AstraZeneca, Pfizer, Novartis, and GlaxoSmithKline.

Summit Therapeutics Inc is a renowned biotechnology company specializing in developing innovative medicines for patients with rare diseases. Founded in 2003, Summit Therapeutics has made significant strides in the field of precision medicine. With a strong focus on genetic diseases, the company uses its proprietary technologies to discover and advance promising therapeutics options. Summit Therapeutics Inc has a track record of successful collaborations with renowned academic institutions and pharmaceutical companies, diversifying its pipeline and expanding its research capabilities. By combining cutting-edge science and strategic partnerships, Summit Therapeutics strives to improve the lives of patients worldwide with groundbreaking treatments and therapies.

Summit Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase II clinical trials for its lead antibiotic candidate, Ridinilazole, demonstrating its effectiveness in treating Clostridium difficile infection. Summit Therapeutics also received Fast Track designation from the U.S. FDA for Ridinilazole, speeding up the review process. In addition, the company secured a collaboration with the Bill & Melinda Gates Foundation to develop new antibiotics targeting gonorrhea, emphasizing their commitment to addressing antimicrobial resistance. Moreover, Summit Therapeutics listed on NASDAQ exchange, enhancing its visibility and accessibility to investors. These milestones highlight the company's progress and dedication to advancing innovative therapies to address unmet medical needs.

Summit Therapeutics Inc is primarily present in the United States and the United Kingdom. They have established their headquarters in Cambridge, Massachusetts, USA, and have an additional office in Oxfordshire, England. The company specializes in the discovery and development of novel medicines to treat rare diseases and infectious diseases. With a focus on innovative research and collaboration, Summit Therapeutics Inc aims to deliver transformative therapies that address significant unmet medical needs.

Summit Therapeutics Inc represents values of innovation, dedication, and commitment to improving patient outcomes. With a strong corporate philosophy focused on advancing breakthrough treatments, Summit is renowned for its cutting-edge research and development initiatives in the pharmaceutical industry. The company strives to leverage its expertise and strategic partnerships to deliver high-quality therapies and address unmet medical needs. Summit Therapeutics Inc's commitment to scientific excellence and patient-centric approach makes it an industry leader, dedicated to transforming healthcare and making a positive impact on people's lives.

Analysts currently set an average price target of 33.13 USD for the Summit Therapeutics stock (median: 35.50 USD), implying +233.0 % versus the latest price. The consensus is based on 24 analyst ratings.

24 analysts currently rate the Summit Therapeutics stock: 17 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Summit Therapeutics to generate revenue of 3.22 M USD and earnings per share of -1.07 USD.

Converted at the current exchange rate, the Summit Therapeutics share trades at 9.07 EUR (9.95 USD).

The Summit Therapeutics share (SMMT) is listed on 1 stock exchanges, including: NASDAQ (SMMT).

Summit Therapeutics Inc. is a biopharmaceutical company specializing in the discovery and development of innovative therapeutic options for rare diseases. The company is headquartered in Oxford, United Kingdom, and also operates locations in the United States. The business model of Summit Therapeutics primarily focuses on identifying and developing medical treatment options for genetically inherited diseases. The company combines comprehensive research and development, strategic partnerships, and careful market research to offer a wide range of products and services. Summit Therapeutics' research area is dedicated to identifying biomarkers and disease mechanisms that play a role in rare diseases. The company utilizes cutting-edge technology and analytical approaches to advance groundbreaking developments in this field. Summit Therapeutics also collaborates closely with external partners to exchange resources and expertise and create synergies. The company has strategic partnerships with leading institutions such as the Children's Hospital of Philadelphia and the University of Oxford, as well as biotech and pharmaceutical companies like Japanese company Sarepta and Swiss company Lonza. Summit Therapeutics' products include a range of drugs in the clinical development stage for the treatment of neuromuscular disorders such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). The company also has an active research branch focused on developing drugs to combat diseases such as C. difficile infections and cystic fibrosis. In addition to these core activities, Summit Therapeutics also offers a wide range of services including consulting, drug discovery platforms, partnering, and clinical development. These services are tailored to the needs of pharmaceutical companies and academic institutions, aiming to accelerate their research and development activities. Overall, Summit Therapeutics has a differentiated business model focused on identifying and developing therapeutic options for rare diseases. The company strives to be a leader in this field by leveraging its innovative research and strategic partnerships to offer a wide range of products and services.

The expected revenue of Summit Therapeutics is 3.22 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Summit Therapeutics is -769.98 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Summit Therapeutics is currently -9.29. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Summit Therapeutics stock.

The price-to-sales ratio (P/S) of Summit Therapeutics is currently 2,220.58. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Summit Therapeutics stock.

The Eulerpool Quality Score for Summit Therapeutics is 3/10.

The ISIN of Summit Therapeutics is US86627T1088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Summit Therapeutics is SMMT. The ticker symbol is used to trade Summit Therapeutics shares on the stock exchange.

Fair ValueTerminal
9.25 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Oct 14, 2004
ISIN
US86627T1088
Cusip
86627T108
Sedol
BMTVQS7
Market capitalization
7.15 B USDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-8.93
P/Ee 2026
-9.29
P/Ee 2027
-9.88
P/Ee 2028
-15.43
P/Ee 2029
68.84
P/S
P/Se
167.22
EV/EBIT
—
P/B Ratio
18.39
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-56.93 %
Last updated Nov 22, 2026, 3:42 AM

Summit Therapeutics Ticker

NASDAQ · SMMT

Summit Therapeutics FIGI

SMMT:US · BBG00X3GQL76SMMT:UA · BBG00X3GR1N1SMMT:UC · BBG00X3GR1P9SMMT:UN · BBG00X3GR1R7SMMT:UP · BBG00X3GR1S6SMMT:UQ · BBG00X3GR1T5SMMT:UB · BBG00X3GR1W1SMMT:UM · BBG00X3GR1Y9SMMT:UX · BBG00X3GR204SMMT:UD · BBG00X3GR259SMMT:UF · BBG00X3GR286SMMT:VY · BBG00X3GR295